These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 20199181

  • 21. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA, Khosla N, Bakris GL.
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [Abstract] [Full Text] [Related]

  • 22. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 23. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 24. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M, Pruijm M, Wuerzner G.
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [Abstract] [Full Text] [Related]

  • 25. [Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure].
    Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, Domínguez-Gil B, Hernández E, Praga M.
    Nefrologia; 2004 Aug; 24(6):546-52. PubMed ID: 15683026
    [Abstract] [Full Text] [Related]

  • 26. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
    Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Io H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S.
    J Nephrol; 2011 Aug; 24(6):756-63. PubMed ID: 21360472
    [Abstract] [Full Text] [Related]

  • 27. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [Abstract] [Full Text] [Related]

  • 28. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 29. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 30. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL, Townsend RR.
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [Abstract] [Full Text] [Related]

  • 31. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K.
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [Abstract] [Full Text] [Related]

  • 32. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F.
    J Nephrol; 2001 Nov; 14(1):15-8. PubMed ID: 11281338
    [Abstract] [Full Text] [Related]

  • 33. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Nov; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 34. Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
    Waeber B, Weidmann P, Wohler D, Le Bloch Y.
    Am J Hypertens; 1996 Dec; 9(12 Pt 1):1220-7. PubMed ID: 8972894
    [Abstract] [Full Text] [Related]

  • 35. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 36. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification.
    Robles NR, Velasco J, Espinosa J, Mena C, Angulo E, Micrex Group Investigators.
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):333-9. PubMed ID: 20647247
    [Abstract] [Full Text] [Related]

  • 37. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
    Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1997 Sep; 12 Suppl 2():53-6. PubMed ID: 9269701
    [Abstract] [Full Text] [Related]

  • 38. Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
    Masunaga Y, Tabei K, Takeda S, Ando Y, Kusano E, Asano Y.
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):961-6. PubMed ID: 8255007
    [Abstract] [Full Text] [Related]

  • 39. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.
    Farah R, Shurtz-Swirski R.
    Minerva Cardioangiol; 2008 Oct; 56(5):467-76. PubMed ID: 18813182
    [Abstract] [Full Text] [Related]

  • 40. [Are all antihypertensive drugs renoprotective?].
    Wolf S, Risler T.
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.